Biogen Idec/Elan Resubmit Tysabri With New Risk Management Program
The multiple sclerosis therapy, which was withdrawn for safety reasons in February, could return to the market by late March 2006.
The multiple sclerosis therapy, which was withdrawn for safety reasons in February, could return to the market by late March 2006.